Nobuko Mibu,<sup>a</sup> Kazumi Yokomizo,<sup>b</sup> Takeshi Miyata,<sup>b</sup> and Kunihiro Sumoto<sup>a</sup>\*

<sup>a</sup>Faculty of Pharmaceutical Sciences,

Fukuoka University, 8-19-1 Nanakuma, Jonan-Ku, Fukuoka 814-0180, Japan

<sup>b</sup>Faculty of Pharmaceutical Sciences, Sojo University, 4-22-1 Ikeda, Kumamoto 862-0082, Japan

\*E-mail: kunihiro@adm.fukuoka-u.ac.jp

Received October 16, 2009

DOI 10.1002/jhet.457

Published online 24 August 2010 in Wiley Online Library (wileyonlinelibrary.com).



Some molecular modifications were attempted to find antiviral active compounds in the class of triarylmethanes against herpes simplex virus type 1 (HSV-1). All the synthesized compounds were evaluated for antiviral activity with HSV-1 by a plaque reduction assay. Some of the compounds showed significant antiviral activities.

J. Heterocyclic Chem., 47, 1434 (2010).

## **INTRODUCTION**

In our synthetic studies on antiviral compounds, we found that some triarylmethane derivatives showed significant activity against herpes simplex virus type 1 (HSV-1) in a plaque reduction assay [1–3]. Most of the compounds, which were synthesized previously, showed a wide range of activities against the HSV-1 virus. Molecular modifications of this class of compounds seemed interesting, and we therefore carried out further synthetic investigation and evaluation of this new class of derivatives.

In this series, we recently reported that the triarylmethane scaffold derivative 1a showed a higher level of antiviral activity (EC<sub>50</sub> =  $2.1 \mu$ M) and lower cytotoxicity (IC<sub>50</sub> = 79.3  $\mu$ M) than those of the corresponding 4,4'-dihydroxytriphenylmethane derivative 2, showing antiviral activity (EC<sub>50</sub> = 5.5  $\mu$ M, IC<sub>50</sub> = 38.1  $\mu$ M) [1]. Compound 1a is composed of a heterocyclic methylenedioxy group instead of the 4-methoxyphenyl group in 2. Phosphorylated aciclovir and many nucleoside phosphates have also shown significant antiviral activity [4-6]. A methane-based symmetrical tri-indolemethane 3 for enhancement of chemically induced HL-60 cell differentiation has recently been reported [7]. The corresponding tri-indolemethyl cation (turbomycin A) was isolated from soil microbial DNA, and it exhibited broad antibiotic activity against gram-negative and gram-positive organisms [8]. Therefore, the alteration of a phenyl ring to other heterocycles or the introduction of phosphoryl ester functionalities into the products has attracted our attention as a potential approach to find new antiviral active compounds.

We describe here, the preparation of some new heteroaryl (pyridine or pyrrole ring)-substituted triarylmethane derivatives. For the purpose of structural comparison nonheterocyclic 4,4',4''-trihydroxytriphenylmethane **4a** was chosen. We also attempted the transformation of hydroxyl groups of products to phosphoryl ester functionalities. Results of plaque reduction assays to assess the anti-HSV-1 activities of these compounds are also presented.

### **RESULTS AND DISCUSSION**

**Chemistry.** We have already reported [1] the procedure for synthesis of compound **1a** by condensation of phenol and aldehyde using various Brønsted acids. The reaction of phenol and aldehyde (piperonal) with sulfuric acid in the shade for **1a** improved the yield to 93%.

Heteroaryl-substituted triarylmethane derivatives 5a or 7 containing pyridine or pyrrole rings were easily synthesized in excellent yield by the reaction of phenol and nicotinaldehyde or the reaction of pyrrole and vanillin using trifluoroacetic acid (TFA) as a Brønsted acid. For compound **6a**, the reaction of bromomagnesium phenolate of sesamol with nicotinaldehyde at a reaction

# Synthesis and Antiviral Activities of Some Heteroaryl-Substituted Triarylmethanes

#### Table 1

Physical data of triarylmethane derivatives (1 and 4-7)



	$mp(^{\circ}C)(P_{\text{correct column}})$		Analysis (%) Calcd (Found)		Calcd	Eermula UD MS	
Compound	Appearance	Formula	С	Н	Ν	m/z Calcd (Found)	IR (cm <sup>-1</sup> ) (KBr)
1b	Pale yellow oil	$\begin{array}{c} C_{28}H_{34}O_{10}P_2 \\ \cdot \ 1.5H_2O \end{array}$	54.28 (54.36	6.02 6.29	0.00 0.00)	$C_{28}H_{35}O_{10}P_2 (M + H)^+$ 593.1705 (593.1705)	3490 (OH) 1275 (P=O) 1030 (P=O)
4b	Pale yellow oil	$\begin{array}{c} C_{31}H_{43}O_{12}P_{3} \\ \cdot \ 2.5H_{2}O \end{array}$	49.94 (49.95	6.49 6.43	0.00 0.00)	$C_{31}H_{44}O_{12}P_3 (M + H)^+$ 701.2046 (701.2046)	3500 (OH) 1270 (P=O) 1025 (P=O)
5a	239–244 (CH <sub>3</sub> CN-H <sub>2</sub> O) colorless powder	$\begin{array}{c} C_{18}H_{15}NO_{2} \\ \cdot \ 0.2H_{2}O \end{array}$	76.96 (77.03	5.53 5.56	4.99 5.16)	$C_{18}H_{16}NO_2 (M + H)^+$ 278.1181 (278.1182)	3240 (OH) 1260 (C—O) 1105 (C—O)
5b	Pale yellow viscous solid <sup>a</sup>	$\begin{array}{c} C_{26}H_{33}NO_8P_2 \\ \cdot \ 0.3H_2O \end{array}$	56.28 (56.27	6.10 6.18	2.52 2.50)	$C_{26}H_{34}NO_8P_2 (M + H)^+$ 550.1760 (550.1757)	3500 (OH) 1275 (P=O) 1030 (P=O)
6b	Yellow oil	$\begin{array}{c} C_{28}H_{33}NO_{12}P_2 \\ \cdot \ 0.8H_2O \end{array}$	51.59 (51.63	5.35 5.34	2.15 2.11)	$C_{28}H_{34}NO_{12}P_2 (M + H)^+$ 638.1556 (638.1557)	3495 (OH) 1275 (P=O) 1025 (P=O)
7	117-120 ( <i>iso</i> -PrOH) pale purple crystals	$C_{16}H_{16}N_2O_2$	71.62 (71.64	6.01 6.09	10.44 10.43)	$\begin{array}{c} C_{16}H_{16}N_{2}O_{2} \ (M^{+})\\ 268.1212\\ (268.1214) \end{array}$	3420 (OH) 3320 (NH) 1230 (C—O)

<sup>a</sup> Consistent and correct mp could not be obtained because this compound is a viscous material.

temperature of 30°C and a long reaction time (2 d) gave an excellent result (84% yield).

The phosphorylation of hydroxyl groups of tri- or dihydroxytriarylmethanes **1a** and **4–6b** gave tris- or bis- phosphoryl esters (**1b** and **4–6a**) by the reported procedures [9,10]. Thus, the phosphorylation of hydroxygroups was accomplished by a slight excess of (EtO)<sub>2</sub>POH in the presence of Et<sub>3</sub>N in CCl<sub>4</sub> from 0°C to room temperature overnight to give the products **1b** and **4–6b** in 11–89% yields. Compounds **5b** and **6b** were obtained under the conditions of a slight excess of (EtO)<sub>2</sub>POCl in the presence of NaH at room temperature for 1 h in 43% and 66% yields, respectively. In both methods, the yields of phosphorylated products depend on the solubility of the starting tri- or dihydroxytriarylmethanes. In fact, the addition of THF or DMF to improve the solubility of the reaction solvent resulted in better yields of the corresponding phosphorylated products (see experimental).

All of the structures of the new compounds synthesized were determined by using spectroscopic data and elemental analyses, and the signal assignments were confirmed by 2D-NMR analyses (Tables 1 and 2).

## **Biological activities**

Antiviral activities. The anti-HSV-1 activities of the synthesized compounds were estimated by using plaque reduction assays in Vero cells [11]. The results of the assays are summarized in Table 3 together with the data for the original compounds 1a [1] and 6a [1].

Substitution with a pyridine ring (compound 5a) resulted in antiviral activity (EC<sub>50</sub> = 6.8  $\mu$ M, IC<sub>50</sub> =

<sup>a</sup> 1 and 4-6b were measured in CDCl<sub>3</sub>; 5a and 7 were measured in DMSO- $d_6$  and CD<sub>3</sub>OD, respectively. <sup>b</sup>Two signals coincided.

Table 2

 $^{13}\text{C-}$  and  $^{1}\text{H-NMR}$  data of triarylmethane derivatives (1 and 4—7) (ô ppm, J Hz).<sup>a</sup>

 $\label{eq:Table 3} Table \ 3$  Antiviral activity (EC\_{50}) and cytotoxicity (IC\_{50}) against HSV-1.

	EC <sub>50</sub> (µM)	$I \ C_{50} \ (\mu M)$	IC50/EC50
1a <sup>a</sup>	2.1	79.3	38.2
1b	>16	21.3	<1.3
4a	22.6	127	5.6
4b	8.6	19.8	2.3
5a	6.8	54.1	7.9
5b	>36	39.6	<1.1
<b>6a</b> <sup>a</sup>	7.3	>135	>18.5
6b	49.1	87.6	1.8
7	>150	190	<1.3

<sup>a</sup> The data of the compounds from [1].

54.1  $\mu$ M) similar to that of compound **6a** (EC<sub>50</sub> = 7.3  $\mu$ M, IC<sub>50</sub> > 135  $\mu$ M) previously reported [1]; however, its cytotoxicity was increased to that of 2,2'-dihydroxy-triarylmethane **6a**. The introduction of two pyrrole rings with an N—H group (compound **7**) resulted in no significant antiviral activity at a concentration of 150  $\mu$ M. Thus, two hydroxyl groups on the triphenylmethane scaffold might be necessary to show significant antiviral potency.

The phosphorylation of hydroxyl groups of 1a, 5a, and 6a resulted in increased cytotoxicity in both transformations into 1b, 5b, and 6b, respectively. Transformation of nonheterocyclic derivative 4a into 4b also showed a similar tendency. Phosphorylated triphenylmethane derivative 4b showed a higher level of antiviral activity than that of original compound 4a, but antiviral activities of both heteroaryl-substituted derivatives 5b and 6b were lower than those of the corresponding 5a and 6a, respectively. With reference to the phosphorylated hetero-ring substituted derivative 1b, its antiviral activity was also lower than that of the corresponding nonphosphorylated original compound 1a. Compounds synthesized in this study showed inhibitory concentrations (EC<sub>50</sub>) ranging from 6.8 to  $> 150 \mu$ M. Among these compounds, we found that 5a has the highest level of activity against HSV-1 (EC<sub>50</sub> = 6.8  $\mu$ M), but its selectivity index was 7.9.

In this study on modification of triarylmethanes by alteration of heteroaryl rings and transformation into phosphorylated derivatives, unfortunately, we could not find more potent antiviral compounds than the 4,4'-dihydroxytriarylmethane **1a** reported previously [1]. Throughout this work, however, it is notable that compounds **5a** and **6a** containing a heteroaryl group (pyridine) showed higher levels of antiviral activity than that of  $C_3$  symmetrical 4,4',4"-trihydroxytriphenylmethane **4a** (EC<sub>50</sub> = 22.6 µM), and the  $C_3$  symmetry structure of both compounds (a prochiral symmetrical molecule) was destroyed by introducing a different heteroaryl ring in

the molecule. To elucidate these phenomena, further molecular modifications of triarylmethanes and evaluation of their activity against HSV-1 are underway.

### **EXPERIMENTAL**

Melting points were determined using a micro melting point apparatus (Yanagimoto MP-S3) without correction. IR spectra were measured by a Shimadzu FTIR-8100 IR spectrophotometer. Low- and high-resolution mass spectra (LR-MS and HR-MS) were obtained by a JEOL JMS HX-110 double-focusing model equipped with a FAB ion source interfaced with a JEOL JMA-DA 7000 data system. <sup>1</sup>H- and <sup>13</sup>C-NMR spectra were obtained by JEOL JNM A-500. Chemical shifts were expressed in  $\delta$  ppm downfield from an internal tetramethylsilane signal for <sup>1</sup>H-NMR and the carbon signal of the corresponding solvent [CDCl<sub>3</sub> (77.00 ppm), CD<sub>3</sub>OD (39.50 ppm), and dimethyl sulfoxide (DMSO)-d<sub>6</sub> (39.50 ppm)] for <sup>13</sup>C-NMR. Microanalyses were performed with a Yanaco MT-6 CHN corder. Routine monitoring of reactions was carried out using precoated Kieselgel 60F<sub>254</sub> plates (E. Merck). Centrifugal or flash column chromatography was performed on silica gel (Able-Biott or Fuji Silysia FL60B, respectively) with a UV detector. Preparation of compounds (1a [1], 4a [1], and 6a [4]) have already been reported. Commercially available starting materials including 4a were used without further purification.

**4,4'-(1,3-Benzodioxol-5-ylmethylene)bisphenol (1a) [1].** To a solution of phenol (755 mg, 8.0 mmol) and 3,4-methylenedioxybenzaldehyde (600 mg, 4.0 mmol) in AcOH (2.3 mL) was added conc.  $H_2SO_4$  (0.43 mL, 8.0 mmol). In the shade, the solution was stirred for 20 h at room temperature. The reaction mixture was poured into ice water (50 mL) and extracted from AcOEt (100 mL × 3). The organic layer was washed with brine and dried over MgSO<sub>4</sub>. After evaporation, the residue was purified by centrifugal chromatography on silica gel (1% EtOH/CH<sub>2</sub>Cl<sub>2</sub>) to give **1a** (1.192 g, 3.7 mmol, 93% yield). Recrystallization from water/*iso*PrOH gave pale reddish crystals.

General procedure of phosphorylation for preparation of 4,4'-(1,3-benzodioxol-5-ylmethylene)bisphenylphosphoric acid tetraethyl ester (1b). This compound was prepared according to the method reported by Huffman *et al.* [9]. Thus, diethyl phosphite (3.6 mmol) was added to a stirred solution of 1a (1.5 mmol) in CCl<sub>4</sub> (5 mL) at 0°C, followed by the addition of Et<sub>3</sub>N (4.2 mmol) dropwise. The reaction mixture was stirred overnight at 0°C to room temperature for 18 h. After dilution with CH<sub>2</sub>Cl<sub>2</sub>, the resulting mixture was washed with water, 10% aqueous HCl, and brine and then dried over MgSO<sub>4</sub>. After filtration and evaporation, the residue was purified by centrifugal chromatography (SiO<sub>2</sub>: 30–40% AcOEt in *n*-hexane), which gave 1b (0.281 mmol, 19% yield) as a pale yellow oil.

**4,4',4"-Methylidynetriphenyl-phosphoric acid hexaethyl ester (4b).** In a manner similar to that for the preparation of **1b**, after reaction of **4a** (2.0 mmol) in CCl<sub>4</sub> (3 mL), diethyl phosphite (7.4 mmol) and Et<sub>3</sub>N (8.2 mmol) at temperatures in the range of 0°C to room temperature for 17 h, purification by flash chromatography (SiO<sub>2</sub>: 2–10% EtOH in CH<sub>2</sub>Cl<sub>2</sub>) gave **4b** (1.78 mmol, 89% yield) as a pale yellow oil. **4,4'-(3-Pyridinylmethylene)bisphenol** (**5**a). A mixture of phenol (941 mg, 10.0 mmol) and nicotinaldehyde (536 mg, 5.0 mmol) and TFA (3.85 mL, 50 mmol) was stirred in the shade at room temperature for 20 h. After evaporation, purification by centrifugal chromatography (50–70% AcOEt in *n*-hexane) gave **5a** (1.380 g, 5.0 mmol) as a colorless solid quantitatively. Recrystallization from CH<sub>3</sub>CN—H<sub>2</sub>O gave an analytically pure colorless powder **5a**.

4,4'-(3-Pyridinylmethylene)bisphenylphosphoric acid tetraethyl ester (5b)

*[Method A].* In a manner similar to that for the preparation of **1b**, after the reaction of **5a** (1.0 mmol) in  $CCl_4$  (3 mL), diethyl phosphate (3.7 mmol), and  $Et_3N$  (4.1 mmol) in the range of 0°C to room temperature for 18 h, purification by centrifugal chromatography (SiO<sub>2</sub>: 3–5% EtOH in CH<sub>2</sub>Cl<sub>2</sub>) gave **5b** (0.281 mmol, 11% yield) as a pale yellow viscous solid.

*[Method B].* According to the method reported by Asaad *et al* [10], NaH (60% in oil, 10 mmol) was added to a stirred solution of **5a** (1.0 mmol) in dry THF-CH<sub>2</sub>Cl<sub>2</sub> (1, 3 mL) at room temperature under an N<sub>2</sub> atmosphere. After stirring for 0.5 h, diethyl chlorophosphate (3.0 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was added to the reaction mixture dropwise for 20 min and then stirred for more 1 h. The reaction mixture was then poured into a saturated NaHCO<sub>3</sub> solution (40 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (30 mL × 2), and its organic layer was washed with water, dried over MgSO<sub>4</sub>, and evaporated. The resulting products were purified by centrifugal chromatography (SiO<sub>2</sub>: 5% EtOH in CH<sub>2</sub>Cl<sub>2</sub>) to give **5b** (0.432 mmol, 43% yield).

6,6'-(3-Pyridinylmethylene)bis-1,3-benzodioxol-5-ol (6a) [1]. Under N<sub>2</sub> atmosphere, a solution of sesamol (2.76 g, 20.0 mmol) in dry ether (Et<sub>2</sub>O; 50 mL) was added dropwise to a solution of 3 M EtMgBr (6.7 mL, 20 mmol) in dry Et<sub>2</sub>O (60 mL) with stirring at room temperature, and the mixture was kept for 10 min, then the solvent was removed in vacuo. After addition of dry CH<sub>2</sub>Cl<sub>2</sub> (300 mL) to the residue, a solution of nicotinaldehyde (536 mg, 5.0 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (50 mL) was added with stirring under N<sub>2</sub> atmosphere. The resulting mixture was sonicated at 30°C for 2 days. The reaction was quenched with saturated aqueous NH<sub>4</sub>Cl (100 mL), and the mixture was extracted with AcOEt (100 mL  $\times$  3). The organic layer was dried over MgSO4 and concentrated in vacuo to give the solid. The residue was recrystallized from MeOH to give 6a as a pale green powder (1.53 g, 4.2 mmol) in 84% yield.

Preparation of 6,6'-(3-pyridinylmethylene)bis-1,3-benzodioxol-5-ylphosphoric acid tetraethyl ester (6b)

*[Method A].* In a manner similar to that of the preparation of **1b**, after reaction of **6a** (1.0 mmol) in CCl<sub>4</sub> (3 mL), diethyl phosphite (3.7 mmol), and Et<sub>3</sub>N (4.1 mmol) at temperatures in the range of 0°C to room temperature for 18 h, purification by centrifugal chromatography (SiO<sub>2</sub>: 3-5% EtOH in CH<sub>2</sub>Cl<sub>2</sub>) gave **6b** (0.505 mmol, 51% yield) as a yellow oil.

*[Method B].* In a manner similar to that for the preparation of **5b**, after the reaction of **6a** (1.0 mmol) in dry THF-CH<sub>2</sub>Cl<sub>2</sub>-

DMF (3, 3, 2 mL) and 60% NaH (2.6 mmol) with diethyl chlorophosphate (2.4 mmol) in dry  $CH_2Cl_2$  (2 mL) for 1.5 h, the reaction mixture was poured into a saturated NaHCO<sub>3</sub> solution (50 mL) and extracted with AcOEt (40 mL × 3). Centrifugal chromatography (SiO<sub>2</sub>: 70–100% AcOEt in *n*-hexane) gave **6b** (0.663 mmol, 66% yield) as a yellow oil.

**2,2'-[(4-Hydroxy-3-methoxy-phenyl)methylene]bis-1H-pyrrol** (7). A mixture of pyrrole (16.4 mL, 240 mmol) and vanillin (912 mg, 6.0 mmol) and TFA (94  $\mu$ L, 1.2 mmol) was stirred in the shade at room temperature for 20 h. After evaporation, purification by flash chromatography (5% AcOEt in CHCl<sub>3</sub>) gave 7 (1.288 g, 4.8 mmol) as a colorless solid in 80% yield. Recrystallization from *iso*-PrOH gave analytically pure pale violet crystals 7.

Antiviral activity assay and cytotoxicity of target compounds. The antiviral activities of synthesized compounds were measured using a plaque reduction assay [11] as described in our previous article [1]. Results of antiviral activity ( $EC_{50}$ ) and cytotoxicity values ( $IC_{50}$ ) with Vero cells are summarized in Table 3.

Acknowledgments. The authors would like to thank Mr. Masahiko Ishii, Mr. Junya Ueno, and Ms Yoko Tomioka for their valuable technical assistance.

### **REFERENCES AND NOTES**

[1] Mibu, N.; Yokomizo, K.; Uyeda, M.; Sumoto, K. Chem Pharm Bull 2005, 53, 1171.

[2] Mibu, N.; Yokomizo, K.; Uyeda, M.; Sumoto, K. Chem Pharm Bull 2003, 51, 1325.

[3] Mibu, N.; Sumoto, K. Chem Pharm Bull 2000, 48, 1810.

[4] Yamanaka, G.; Tuomari, A. V.; Hagen, M.; McGeever-Rubin, B.; Terry, B.; Haffey, M.; Bisacchi, G. S.; Field, A. K. Mol Pharmacol 1991, 40, 446.

[5] Elion, G. B.; Furman, P. A.; Fyfe, J. A.; De Miranda, P.; Beauchamp, L.; Schaeffer, H. J. Proc Natl Acad Sci USA 1977, 74, 5716.

[6] De Clercq, E.; Andrei, G.; Balzarini, J.; Leyssen, P.; Naesens, L.; Neyts, J.; Pannecouque, C.; Snoeck, R.; Ying, C.; Hockova, D.; Holy, A. Nucleos Nucleot Nucl 2005, 24, 331.

[7] Noguchi-Yachide, T.; Tetsuhashi, M.; Aoyama, H.; Hashimoto, Y. Chem Pharm Bull 2009, 57, 536.

[8] Gillespie, D. E.; Brady, S. F.; Bettermann, A. D.; Cianciotto, N. P.; Liles, M. R.; Rondon, M. R.; Clardy, J.; Goodman, R. M.; Handelsman. J. Appl Environ Microbiol 2002, 68, 4301.

[9] Huffman, J. W.; Miller, J. R. A.; Liddle, J.; Yu, S.; Thomas, B. F.; Wiley, J. L.; Martin, B. R. Bioorg Med Chem 2003, 11, 1397.

[10] Asaad, N.; Kirby, A. J. J Chem Soc Perkin Trans 2 2002, 1708.

[11] Schinazi, R. F.; Peters, J.; Williams, C.; Chance, D.; Nahmias, A. Antimicrob Agents Chemother 1982, 22, 499.